UMnu. X sisigulana esikwiminyaka engama-40 ubudala esafunyaniswa sine-acral melanoma. Emva kotyando olukhulu emva kokufunyaniswa kwakhe ngo-2015, imeko yakhe yahlala izinzile kangangeminyaka elithoba. Ngelishwa, malunga nonyaka ophelileyo, isifo sakhe saphinda savela kunye ne-metastases kwimiphunga yomibini. Nangona wafumana i-inguinal kunye ne-pelvic lymph node dissection kunye nonyango lwe-third-line systemic (kuquka unyango lwe-PD-1 antibody kunye nonyango olujoliswe kwi-NRAS mutation), amathumba achaphazele kakhulu imiphunga yomibini, i-groin, izicubu ezingaphantsi kolusu lwasekunene lwesisu, kunye nemisipha ye-bilateral erector spinae, nto leyo ekhokelela kwintlungu enzima kunye nokuhla okukhulu komgangatho wobomi.
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
Ekuqaleni kuka-2025, uMnu. X wathatha inxaxheba kuvavanyo lweklinikhi lwe-TIL cell therapy (GC101) waza wagqiba ukufakwa kwe-TIL cell infusion ekuqaleni kukaJuni. Nangona umthwalo wakhe wesimila wawunzima, isilonda esikhulu sasimalunga ne-62 mm, kwiiveki ezintandathu emva kokufakwa, izilonda zakhe ezijoliswe kuzo zinciphe nge-31.9%, kwaye isilonda esinye esikhulu sincipha phantse nge-40%. Ukusebenza kakuhle konyango kufikelele kwimpendulo engaphelelanga (PR). Okubaluleke ngakumbi, uMnu. X akazange afumane naziphi na iziphumo ezimbi emva konyango lwe-GC101 TIL, kuphela iziphumo ebezingalindelekanga ezinxulumene ne-immunotherapy ezifana nokugodola kunye nomkhuhlane, ezaphela ngokukhawuleza ngonyango oluneempawu.
Malunga ne-GC101
I-GC101 lunyango lwendalo lwe-TIL TIL oluphuhliswe kusetyenziswa iqonga lokukhulisa iiseli ze-DeepTIL® zeJuncell Therapeutics. I-DeepTIL® ivumela ii-TIL ukuba zibe namandla ngokwaneleyo kangangokuba akukho ndibaniselwano ye-IL-2 eya kufuneka emva kokufakwa, kwaye ubunzulu bonyango lwangaphambi konyango bunokuba sezantsi.
Njengonyango lokuqala lwe-TIL olufuna kuphela unyango oluphantsi kwamandla angaphambi kokuba lusetyenziswe kwaye lungafakwa inaliti ye-IL-2 ehlabathini, i-GC101 iqinisekisiwe ngenxa yokusebenza kwayo kakuhle kunye nokhuseleko oluphucula kakhulu ukhuseleko kunye nokufikeleleka konyango lwe-TIL.
Malunga neMelanoma
ETshayina, izinga lokufa ngenxa ye-melanoma liphezulu kwaye izinga lokuvela kwayo liyanda minyaka le. Xa kuthelekiswa neYurophu okanye iMelika, kukho umahluko omkhulu kwiimpawu ze-melanoma kumaTshayina: malunga ne-90% ye-melanoma ivela eluswini phakathi kwamaYurophu namaMerika. EAsia, malunga ne-50% ye-melanoma ivela eluswini kwaye i-20-30% ikwi-mucous membrane. Ngokwahlukileyo koko, i-melanoma yohlobo lwe-mucous kunye ne-mucosal ine-prognosis embi.
Okwangoku, kusekho iimvavanyo ezininzi zeklinikhi zobuchwepheshe obutsha bokulwa nomhlaza eTshayina obufuna izigulane. Iingcebiso ngamayeza amatsha kunye nobuchwepheshe, ungaqhagamshelana neSebe leMicimbi yeZibhedlele ze-Oncology zaseBeijing South Region.
Inombolo yefowuni: 4008803716
I-ID ye-WeChat: 17801183037
Email：myimmnet@163.com
Ixesha lokuthumela: Agasti-07-2025